FDA Creates a New Regulatory Category for a Brain-Infection Test
Published Date: 6/26/2025
Rule
Summary
The FDA is officially putting the herpes simplex virus test for brain infections into a safer, easier-to-manage category called Class II. This change means the test will have special rules to keep it safe and effective, helping patients get quicker access to this important tool without unnecessary red tape. The new classification is effective June 26, 2025, and could save time and money for makers and users of the test.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Developers Must Meet Detailed Special Controls
If you develop this HSV CNS assay, you must provide detailed design verification and validation documentation, including device description (components, ancillary reagents, primer design), analytical performance data (limit of detection, reactivity, inclusivity, precision, reproducibility, interference, cross-reactivity, carryover, cross-contamination), reagent and sample stability recommendations, a clinical study comparing performance to two PCR methods followed by bidirectional sequencing, an end-user training program, quality assurance protocols, and software documentation.
HSV CNS Test Reclassified to Class II
If you make or sponsor this herpes simplex virus (HSV) nucleic acid test for central nervous system (CNS) infections, the FDA has classified it as Class II (special controls). This order is effective June 26, 2025, the device is subject to premarket notification under section 510(k), and the classification was applicable on March 21, 2014.
De Novo Classification Enables Future 510(k) Predicates
Because FDA used the De Novo process to classify this device into Class II, this device can serve as a predicate for future similar devices, allowing other sponsors to use the less burdensome 510(k) pathway instead of submitting a De Novo request or premarket approval application.
Labeling Must Explain Results and Warn on Negatives
If you use this HSV CNS test, the labeling must give a detailed explanation of how to interpret results and the acceptance criteria, and it must state that negative results do not preclude HSV-1 or HSV-2 infection and should not be used as the sole basis for treatment or other patient management decisions.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-11793, Medical Devices; Hematology and Pathology Devices; Classification of the Fluorescence In Situ Hybridization-Based Detection of Chromosomal Abnormalities From Patients With Hematologic Malignancies
The FDA is officially classifying a special test that spots chromosome problems in blood cancer patients as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make sure the test is safe and effective while speeding up patient access to new, helpful technology. The new rules took effect on June 26, 2025, and could save time and money for companies making these tests.
Next: 2025-11796, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Muscular Dystrophy Newborn Screening Test
The FDA is officially classifying the muscular dystrophy newborn screening test as a Class II device with special controls to ensure it’s safe and effective. This change helps babies get quicker access to this important test by easing some regulatory hurdles. The new classification is effective June 26, 2025, but has been in effect since December 12, 2019, making life easier for test makers and families alike.